RE:TechTarget CXR @ $35 ULTIMATE BUY/trade. Here's a TA chart!TechTarget wrote: Here is a TA chart using an advanced stock analysis tool. Shows the GROSSLY OVERSOLD CONDITIONS that many posters are talking about here today.
Look this TA chart. Last grossly oversold condition ended up seeing the stock go from $46 to $61 CDN in just two days! That an impressive gain. But the shorts managed to get to (with some effort) to bring it down with the final attack happening today.
That's the bad news. The good news is you can now buy cheaper! Likely, the sub $40 CDN are gone, as other traders have indicated on this board, they can see oversold conditions. I also agree that opening will be above $40 tomorrow. All the conditions are right. End of day investors will be reviewing their positions and those with a calm, rational mind will make their decisions.
For CXR, you want to check pre-opening tomorrow. This is where I will be. Expect open in green and possible one hell of a run as these shorts and naked shorts scramble to buy CXR to cover their position! The more people buy, the more the momentum players, penny flippers etc will pile all, all wanting to BUY and competing against the short manipulating crooks. Love seeing shorts run for departing train, little short legs and all! ;-) LOL This is where small, nimble investors can sneak in for BIG GAINS!
None of the great news today needs to be factored in. The TA is telling us this is happening (unless aliens land and take away CXR!) LOL!
With the recent great news, we have rockets that will be going on full force on this. I actually bought today on margins, my cash (investment and speculative) is all parked and I don't want to miss this type of opportunty. Thank you shorts! I LOVE to HATE you! :-) LOL
I can profit from your crimes without getting my hands dirty! LOL
This chart and analysis doesn't even take into account the good news today! As follows!
Concordia allocates $1,865M (U.S.) in term loans
2015-10-20 16:06 ET - News Release
An anonymous director reports
CONCORDIA PROVIDES UPDATE ON TERM LOAN FINANCING AND RECONFIRMS BLENDED INTEREST RATE OF APPROXIMATELY 7.25% POST AMCO ACQUISITION
Concordia Healthcare Corp.'s term loans of approximately $1,865-million (U.S.) (i) ($1.1-billion (U.S.) and 500 million British pounds) being raised in connection with the financing of its acquisition of Amdipharm Mercury Ltd. (AMCo) have been fully allocated to institutional accounts.
The company previously announced fully committed debt financing of approximately $2.8-billion (U.S.). This debt financing will consist of the term loans, the senior notes of $790-million (U.S.) and equity bridge loans in the total amount of $180-million (U.S.). The $2.8-billion (U.S.) of debt financing and $520-million (U.S.) raised from the company's recent public equity offering, along with cash on hand, will be used to finance the purchase price for AMCo, refinance certain Concordia and AMCo debt, and complete the acquisition, which is scheduled to close on or about Oct. 21, 2015.
As previously announced, following the closing of the acquisition, Concordia's total debt, including both new debt and existing notes of $735-million (U.S.), will have a maximum blended interest rate of approximately 7.25 per cent.
(i) Calculated at Oct. 13, 2015, with a U.S.-dollar/British-pound exchange rate of 1.53.